Journal of Pathology and Translational Medicine (대한병리학회지)

The Korean Society of Pathologists (대한병리학회)
권호 표지

MMP-2 and MMP-9 Expressions in Breast Carcinomas and Relationship with Major Prognostic Factors

유방암종의 MMP-2와 MMP-9 발현과 예후 인자와의 연관성

Yoon, Hye-Kyoung;Park, Seol-Mi
윤혜경;박설미

  • Published : 20040000
⟨ Previous Next ⟩

Abstract

MMP-2 and MMP-9 are involved in the degradation of extracellular matrix, and MMP-2 and MMP-9 expressions in breast carcinomas have been reported as a poor prognostic factor. The aim of this study is to evaluate the prognostic value and the regulatory factors of MMP-2 and MMP-9 expressions in 73 cases of infiltrating ductal carcinomas, NOS type. Methods : Immunohistochemistry for MMP-1, -2, -3, -9 and TIMP-1, -2 were performed and evaluation for patient’s age, size, histologic grade, lymph node metastasis and tumor markers such as ER, PR, p53, c-erbB-2, cathepsin D, MIB-1, and microvessel density was done. Results : The expression rates of MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1 and TIMP-2 were 74.0%, 76.7%, 1.4%, 87.7%, 24.7% and 75.3%, respectively. MMP-2 expression rate was higher in the tumors of low and intermediate grade and PR positive tumors (p<0.05), and MMP-9 expression showed an increasing tendency in ER positive tumor (p=0.0676). Positive relationships between MMP-2 and MMP-1 expressions, and MMP-9 and TIMP-2 expressions were recognized (p<0.05). Conclusion : The prognostic significance of MMP-2 and MMP-9 expressions is still unclear, and MMP-2 and MMP-9 expressions seemed to be positively related with MMP-1 and TIMP-2 expression, respectively.

Keywords

References

  1. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992; 10: 145-55. https://doi.org/10.1007/BF00132746
  2. Kurizaki T, Toi M, Tominaga T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep 1998; 5: 673-7.
  3. Dalberg K, Eriksson E, Enberg U, Kjellman M, Backdahl M. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J Surg 2000; 24: 334-40. https://doi.org/10.1007/s002689910053
  4. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 1996; 148: 1345-50.
  5. Jones JL, Walker RA. Control of matrix metalloproteinase activity in cancer. J Pathol 1997; 183: 377-9. https://doi.org/10.1002/(SICI)1096-9896(199712)183:4<377::AID-PATH951>3.0.CO;2-R
  6. Hanemaaijer R, Verheijen JH, Maguire TM, et al. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 2000; 86: 204-7.
  7. Lindsay CK, Thorgeirsson UP, Tsuda H, Hirohashi S. Expression of tissue inhibitor of metalloproteinase and type IV collagenase/gelatinase messenger RNAs in human breast cancer. Hum Pathol 1997; 28: 359-66. https://doi.org/10.1016/S0046-8177(97)90136-2
  8. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066-76. https://doi.org/10.1074/jbc.274.19.13066
  9. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 1996; 87: 602-11. https://doi.org/10.1111/j.1349-7006.1996.tb00266.x
  10. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-36. https://doi.org/10.1016/0092-8674(91)90642-C
  11. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250. https://doi.org/10.1177/10454411930040020401
  12. Sato H, Seiki M. Membrane-type metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem 1996; 119: 209-15. https://doi.org/10.1093/oxfordjournals.jbchem.a021223
  13. Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with nodepositive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 2001; 65: 55-61. https://doi.org/10.1023/A:1006458601568
  14. Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 1998; 16: 577-85. https://doi.org/10.1023/A:1006580415796
  15. Hoyhtya M, Fridman R, Komarek D, et al. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 1994; 56: 500-5. https://doi.org/10.1002/ijc.2910560408
  16. Davies B, Miles DW, Happerfield LC, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993; 67: 1126-31. https://doi.org/10.1038/bjc.1993.207
  17. Soini Y, Hurskainen T, Hoyhtya M, Oikarinen A, Autio-Harmainen H. 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem Cytochem 1994; 42: 945-51. https://doi.org/10.1177/42.7.8014478
  18. Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 1990; 136: 585-92.
  19. Visscher DW, Hoyhtya M, Ottosen SK, et al. Enhanced expression of tissue inhibitor of metalloproteinase-2 in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 1994; 59: 339-44. https://doi.org/10.1002/ijc.2910590308
  20. Min SK, Kim JM, Chu YC, Cho YU, Yeom BW. Association between the expression of MMP-2 and TIMP-2, and growth patterns of tumor border, lymph node metastasis, and estrogen receptor in the invasive ductal carcinoma of the breast. Korean J Pathol 2000; 344: 366-73.
  21. Choi YJ, Jung WH, Lee HD, Lee KG. Expression of matrix metalloproteinase and tissue inhibitor of metalloproteinase in breast carcinoma related to angiogenesis and invasion. Korean J Pathol 2000; 34: 652-64.
  22. Kim DW, Jin SY, Lee DW. Expression of MMP-2, MT1-MMP, and TIMP-2 mRNA in breast carcinomas. Korean J Pathol 2003; 37: 400-6.
  23. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998; 83: 1153-6. https://doi.org/10.1002/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.0.CO;2-4
  24. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat 1999; 58: 287-93.
  25. Hurskainen T, Hoyhtya M, Tuuttila A, et al. mRNA expressions of TIMP-1, TIMP-2 and -3 and 92-KD type IV collgenase in early human placenta and decidual membranes as studied by in situ hybridization. J Histochem Cytochem 1996; 44: 1379-88. https://doi.org/10.1177/44.12.8985130
  26. Davidson B, Goldberg I, Kopolovic J, et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma -A clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999; 73: 372-82. https://doi.org/10.1006/gyno.1999.5381